China SXT Pharmaceuticals Inc (SXTC)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
SXTC
China SXT Pharmaceuticals Inc
$1.36
-3.55%
HEALTHCARE · Cap: $1.20M
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.29
+1.39%
HEALTHCARE · Cap: $56.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 290284564% more annual revenue ($4.46T vs $1.54M). TAK leads profitability with a 2.5% profit margin vs 0.0%. TAK earns a higher WallStSmart Score of 60/100 (C).
SXTC
Hold41
out of 100
Grade: D
TAK
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for SXTC.
Margin of Safety
-77.5%
Fair Value
$10.30
Current Price
$18.29
$7.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 42.6% YoY
Growing faster than its price suggests
Reasonable price relative to book value
Generating 317.5B in free cash flow
Large-cap with strong market position
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -50.3% — below average capital efficiency
Revenue declined 24.5%
4.2% revenue growth
3.3% earnings growth
ROE of 1.5% — below average capital efficiency
2.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : SXTC
The strongest argument for SXTC centers on Price/Book, EPS Growth.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.39 suggests the stock is reasonably priced for its growth.
Bear Case : SXTC
The primary concerns for SXTC are Market Cap, Profit Margin, Return on Equity.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, EPS Growth, Return on Equity. A P/E of 82.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
SXTC carries more volatility with a beta of 1.74 — expect wider price swings.
TAK is growing revenue faster at 4.2% — sustainability is the question.
TAK generates stronger free cash flow (317.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TAK scores higher overall (60/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
China SXT Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · China
China SXT Pharmaceuticals, Inc., a pharmaceutical company, is engaged in the research, development, manufacture, marketing and sale of Traditional Chinese Medicine Tablets (TCMP) in China. The company is headquartered in Taizhou, China.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?